Pharmacological management of non-small cell lung cancer

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorWu, Yi-Chen
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.date.accessioned2021-06-18T09:51:52Z
dc.date.available2021-06-18T09:51:52Z
dc.date.created2020-03-13
dc.description.abstractLung cancer is one of the most common cause of death worldwide, while non-small cell lung cancer accounts for 85% of all lung cancer cases. Traditionally, the standard of care was platinum- based chemotherapy. However, with the discovery of a wide variety of driver mutations by molecular diagnostic methods, there has been an explosion of new drugs being approved yearly.The main aim of this review is to discuss the available pharmacotherapy for non-small cell lung cancer according to the stage of the disease and molecular status. Also to give a short review about the background knowledge of non-small cell lung cancer, regarding its histological classification, epidemiology, symptomology, diagnostic methods and treatment options.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent43hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/311329
dc.language.isoenhu_HU
dc.subjectNSCLChu_HU
dc.subjecttyrosine kinase inhibitorhu_HU
dc.subjectcheckpoint inhibitorshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titlePharmacological management of non-small cell lung cancerhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)